The Portfolio · BriefLatest →
M&A

SAGILITY · SAGILITY LIMITED · NSE · Filed 13 Jun · 1 min read

Sagility Acquires U.S. Healthcare Analytics Firm CareSeed in 100% Buyout

Sagility said it has acquired CareSeed, a Kansas City–based NCQA-certified HEDIS quality reporting and healthcare analytics company serving 30 small and mid-sized U.S. payers, in a deal it expects to close on June 11, 2026.

What was filed

Sagility Limited disclosed a press release to the NSE and BSE announcing the acquisition of CareSeed, a U.S.-based healthcare analytics company founded in 2012 and headquartered in Kansas City, Missouri. Per the filing, CareSeed specializes in NCQA-certified HEDIS quality reporting, medical record review, chart abstraction, and regulatory analytics for health plans, and serves small and mid-sized U.S. payers with what the company describes as a strong footprint in Medicare Advantage. The transaction is a 100% acquisition, and the filing states it is expected to close on June 11, 2026 — the same date as the announcement.

What CareSeed brings

The filing describes CareSeed's two cloud-native platforms — Forecast, which provides NCQA-certified HEDIS reporting and quality analytics, and Harvest, which handles medical record review, chart abstraction, and supplemental data capture. Sagility frames the acquisition as a strategic expansion of its healthcare quality and Stars capabilities, aimed at moving health plans from retrospective HEDIS reporting toward integrated, member-level quality orchestration. The company said the deal expands its market reach through new small and mid-sized health plan relationships and strengthens its position in the mid-market payer segment. Houlihan Lokey served as CareSeed's exclusive financial advisor, with Allrise Legal Counsel and Swanson Bernard acting as legal counsel.

Financial framing in the filing

Sagility disclosed CareSeed's reported financials for CY25 and stated the transaction will be EPS accretive. The company characterized the combined offering as creating a platform with recurring revenue and deeper client relationships. No purchase price or consideration figure for the acquisition itself is stated in the filing.

CareSeed CY25 revenue
$5.1 M
CareSeed CY25 EBITDA
$1.6M
CareSeed CY25 EBITDA margin
31.4%
Stake acquired
100%
U.S. payers served by CareSeed
30
New health plan relationships added
28

For a holder, the filing matters as a disclosed inorganic step into U.S. healthcare quality analytics and HEDIS reporting; the company states the deal is EPS accretive, though it does not disclose a purchase price or the financing terms, leaving the consideration undisclosed.